Search

CN-121987766-A - Camel milk source protein and application thereof

CN121987766ACN 121987766 ACN121987766 ACN 121987766ACN-121987766-A

Abstract

The present invention aims to provide the use of camel milk-derived proteins selected from CM4 (camel serum albumin), alpha-LA (camel lactalbumin) or mixtures thereof for the manufacture of a medicament or nutritional supplement for the treatment or prevention of metabolic disorders. The invention solves the problems of side effect limitation, insufficient curative effect and the like of the existing hypoglycemic drugs, realizes safe and effective intervention on diabetes, and finally provides experimental basis and technical support for developing novel hypoglycemic drugs of natural sources.

Inventors

  • YUE HAITAO
  • YIN GUO
  • ZHANG XINYU
  • XUE JIAMIN
  • Chi Xiangyue
  • LI YAXIN

Assignees

  • 新疆大学

Dates

Publication Date
20260508
Application Date
20260319

Claims (10)

  1. 1. Use of a camel milk-derived protein selected from CM4 (camel serum albumin), alpha-LA (camel lactalbumin) or a mixture thereof for the manufacture of a medicament or nutritional supplement for the treatment or prevention of a metabolic disorder.
  2. 2. The use according to claim 1, wherein the metabolic disease is selected from hyperglycemia (type 2 diabetes), insulin resistance, impaired glucose tolerance, hyperlipidemia, obesity or metabolic fatty liver.
  3. 3. The use according to claim 1 or 2, wherein the amino acid sequence of CM4 (camel serum albumin) is shown in SEQ ID No. 1.
  4. 4. The use according to claim 1 or 2, wherein the amino acid sequence of α -LA (camel-derived lactalbumin) is shown in SEQ ID No. 2.
  5. 5. Use according to any one of claims 1 to 4, wherein the camel milk-derived protein comprises CM4 (camel serum albumin) and a-LA (camel lactalbumin).
  6. 6. The use according to claim 5, wherein the metabolic disease is selected from hyperglycemia (type 2 diabetes), insulin resistance, impaired glucose tolerance or hyperlipidemia.
  7. 7. The use according to any one of claims 1 to 6, wherein the medicament or nutritional supplement further comprises an additional medicament or nutritional supplement for the treatment or prevention of metabolic disorders.
  8. 8. The use according to any one of claims 1 to 7, wherein the medicament or nutritional supplement is in the form of a solid, liquid or semi-solid.
  9. 9. The use according to claim 8, wherein the medicament or nutritional supplement is a tablet, capsule, granule, powder, solution, injection, infusion, oral, drop, inhalant, suppository or patch.
  10. 10. The use according to any one of claims 1 to 9, wherein the medicament or nutritional supplement comprises alpha-LA (camel-derived lactalbumin) at a dose of not less than 500 mg/kg and/or CM4 (camel-derived serum albumin) at a dose of not less than 50 mg/kg.

Description

Camel milk source protein and application thereof Technical Field The invention belongs to the technical field of crossing functional foods and biological medicines. More specifically, the invention relates to discovery and separation of camel milk-derived hypoglycemic functional proteins and application thereof in regulation of blood glucose homeostasis and development of products (natural functional foods, dietary supplements, pharmaceutical intermediates and the like) related to adjuvant therapy of type 2 diabetes. Background Diabetes is a chronic metabolic disease that severely threatens human health worldwide, and the number of diabetics worldwide has exceeded 4.6 billion and still grows at a rate of about 3% per year, with type 2 diabetes accounting for over 90%, based on published data published by the World Health Organization (WHO) 2025, has become a significant challenge in the public health field [1]. The existing diabetes intervention means mainly comprise drug treatment, diet regulation and exercise intervention, but the drug treatment has potential side effects such as hypoglycemia, gastrointestinal discomfort and the like, the long-term compliance of the traditional diet regulation is poor, and urgent requirements of patients on safe, natural and multi-target blood glucose steady state regulation means are difficult to meet [2]. In the nutritional and health fields, milk-derived proteins have been widely used as natural functional raw materials in the development of blood glucose regulation-related products [3]. In the prior art, the research on the hypoglycemic activity of conventional milk source (such as cow milk and sheep milk) proteins is mature, but the core defects of single target point and limited regulation effect are common, namely, for example, cow milk proteins can only realize partial blood sugar regulation by promoting insulin secretion, can not effectively improve insulin resistance or regulate key enzyme activities of sugar metabolism, and can not realize comprehensive regulation of blood sugar steady state [4]. In addition, most of the existing functional milk protein products are added by single components, and the existing functional milk protein products lack of accurate design aiming at specific groups (such as pre-diabetes patients) and have limited industrialized application scenes. In recent years, camel milk is taken as a characteristic functional milk source raw material, and the naturally occurring milk source protein has unique molecular structure and biological characteristics, so that the camel milk is increasingly and widely focused by researchers at home and abroad [5]. Compared with the conventional milk-derived protein, the prior basic research proves that the beta-casein accounts for more than 80 percent (only 30-40 percent of cow milk) and the immunoglobulin (IgG) content is higher [6], and the camel milk-derived protein can realize the regulation of the blood sugar steady state through regulating and controlling insulin secretion, improving insulin resistance, regulating the activity of glucose metabolism enzyme and other multi-target-point ways in cell experiments and animal experiments, and has obvious potential advantages in early intervention and auxiliary treatment of type 2 diabetes. In the prior art, whether functional proteins with definite blood sugar regulating activity, specific types, molecular structures and biological characteristics exist in camel milk or not is in an uncertain state, related researches are mostly stopped at a presumption level, and a systematic experiment verification data support is lacked, so that the application research of camel milk protein in the field of blood sugar regulating is slow [7]. Disclosure of Invention Aiming at the problems, the inventor proves that a functional protein with obvious physiological activity does exist in camel milk through a series of targeted experiments, and meanwhile, compared with the conventional milk-derived protein, the protein beta-casein has the proportion of more than 80 percent (only 30-40 percent of cow milk) and the content of immunoglobulin (IgG) is higher. In cell experiments and animal experiments, the camel milk functional protein can realize the regulation and control of blood glucose homeostasis through regulating and controlling insulin secretion, improving insulin resistance, activating signal channels to regulate activity of glucose metabolism enzymes and other multi-target ways, and has obvious potential advantages in early intervention and adjuvant therapy of type 2 diabetes. The invention aims to provide a technical scheme for applying camel milk-derived functional proteins to the regulation of physiological functions of organisms, which takes the biological activity of various functional proteins in camel milk as a core through systematic verification, and defines the roles of the camel milk-derived functional proteins in the improvement of multidimensional physio